mynth
04/2007MajorityLBO

Astorg takes majority stake in Ethypharm

FRANCE Life Sciences / Pharma & Biotech EV €300–700M

Context

Astorg Partners has entered into a definitive agreement to acquire a 60% majority stake in Ethypharm. The transaction follows a competitive sale process that included both industrial players and other private equity funds. The operation marks a resolution to a long-standing governance conflict between the laboratory's founding shareholders. Under the new ownership structure, the management team and current CEO will retain approximately 29% of the capital, while Intermediate Capital Group (ICG) and other minor shareholders will hold the remaining balance. The strategic rationale for the acquisition is to support Ethypharm’s transition from a primarily European player into a global leader in sophisticated galenic forms. Astorg Partners intends to accelerate the laboratory's development in North America, specifically targeting acquisitions to gain a local foothold in that market. The investment aims to capitalize on the target's strong historical growth rate and its specialized technical capabilities. The management team will remain in place to ensure operational continuity and execute the internationalization strategy, focusing on scaling the company’s R&D-driven business model while maintaining its established production excellence in Europe and Asia.

Ethypharm, which reported an EBITDA margin of [members only] in 2007, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Saint-Cloud, Ethypharm is a specialized pharmaceutical group focused on the development and manufacturing of drug delivery systems and galenic forms. The entity maintains a strong therapeutic focus on the central nervous system, particularly in the treatment of pain and addiction, which accounts for nearly half of its total revenue. The business model is built on high-value clinical differentiation and an extensive international reach, with 66% of its commercial activity generated outside of France. The company operates through a global network of over 80 partners and maintains direct subsidiaries in key markets including the United States, Canada, the United Kingdom, Germany, and China. Historically, the firm has strengthened its portfolio through strategic acquisitions, such as Laboratoires Pharmaceutiques Dexo and the British specialist DB Ashbourne. Its value proposition centers on its specialized R&D capabilities and complex manufacturing processes that cater to global pharmaceutical standards.

Ent. Value

€300–700M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2007
€100–200M
€25–50M
[members only]
2006
€100–200M
€25–50M
[members only]

Other operations with Ethypharm

Other operations with Ethypharm
DateAcquirerTargetCountrySector
06/2016PAI PARTNERSETHYPHARMFRANCEPharma & Biotech

Other operations with Astorg

Other operations with Astorg
DateAcquirerTargetCountrySector
03/2021ASTORGXCEPTORUNITED KINGDOMFinancial Services / Banking
06/2020ASTORGNORMECNETHERLANDSTIC (Testing, Inspection, Certification)
04/2020CINVEN / ASTORGLGC GROUPUNITED KINGDOMTIC (Testing, Inspection, Certification)
02/2019ASTORGANAQUAUNITED STATESIndustry-Specific Software
10/2018ASTORGNEMERAFRANCEMedical Consumables
04/2016ASTORGFLOWBIRD (EX PARKEON)FRANCEIndustry-Specific Software
02/2016ASTORG / GOLDMAN SACHSHRA PHARMAFRANCEGenerics / Labs
04/2015ASTORGMETROLOGIC GROUPFRANCESupply Chain & Ops
12/2013ASTORGKERNEOSFRANCEConstruction Materials
11/2007ASTORGTRESCALFRANCETIC (Testing, Inspection, Certification)

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
10/2013ARDIANLABORATOIRES ANIOSFRANCEMedical Consumables
07/2013CHARTERHOUSEDOC GENERICIITALYGenerics / Labs
06/2013BC PARTNERSANTELLIQFRANCEAnimal Health
06/2013EURAZEOPÉTERS SURGICALFRANCEMedical Consumables
01/2013ELITECH GROUPVITAL DIAGNOSTICSUNITED STATESDiagnostic Equipment
08/2012BC PARTNERSAENOVA GROUPGERMANYCDMO
05/2011AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIALAGARRIGUEFRANCEImplants & Prosthetics
09/2010SPARRING CAPITALIMV TECHNOLOGIESFRANCER&D Biotech
09/2009THE CARLYLE GROUPMARLE GROUPFRANCEImplants & Prosthetics
01/2006EDMOND DE ROTHSCHILD CAPITAL PARTNERSACTEONFRANCEMedical Devices

REFERENCES

Valuation range: EV €300–700M

Revenue range: €100–200M

EBITDA range: €25–50M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Ethypharm by Astorg are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: ethypharm

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Ethypharm, a French company specialised in Pharma & Biotech, by Astorg in 2007, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with PAI Partners in June 2016 (see the dedicated deal page for details).

How was the acquisition of Ethypharm by Astorg valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €300–700M band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Ethypharm’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Ethypharm generated annual revenue estimated in the €100–200M range and EBITDA in the €25–50M bracket (FY 2007). Detailed financial figures are available to members.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.